Hoverink

About Hoverink

Hoverink Biotechnologies, Inc. is a preclinical biopharmaceutical and defense company. The company operates through two main segments: the Preclinical Biopharmaceutical Segment (BPS) and the Defense Segment. PitchBook data indicates the company is out of business.

The biopharmaceutical division focuses on developing non-opioid product candidates for various medical needs. Its lead drug candidate, LADAVRU®, is a proprietary opioid alternative designed to manage chronic pain, nausea, and discomfort, particularly for patients with gastrointestinal and oncological diseases. LADAVRU® is a formulation of Dronabinol, a cannabinoid, intended for delivery as an IV injectable or a solid preparation. The company has also mentioned KAIYADRU®, a pharmaceutical preparation for a wide range of diseases, and MAXKAFLEN, aimed as a cost-effective antibiotic solution for the cattle industry.

The Defense Segment is centered on the BODY GLOBE BODY ARMOR® (BGBA). This product is a transparent, dome-shaped body armor made from laminated polycarbonate, designed to offer bullet and blast resistance for military and law enforcement personnel. The design allows users to return fire through a small opening while remaining protected.

In January 2020, Hoverink announced that CEO Debbie Mae Carter would be succeeded by the company's Vice President, Cyrus Sajna, as interim CEO and CFO. The company received $10 million in a seed round on January 30, 2019, and its headquarters is located in Los Angeles, California.